119 related articles for article (PubMed ID: 9250565)
21. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Penninga E; Jensen BA; Hansen PB; Clausen NT; Mourits-Andersen T; Nielsen OJ; Hasselbalch HC
Clin Lab Haematol; 2004 Oct; 26(5):335-40. PubMed ID: 15485463
[TBL] [Abstract][Full Text] [Related]
22. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.
Spencer CM; Brogden RN
Drugs; 1994 May; 47(5):809-22. PubMed ID: 7520859
[TBL] [Abstract][Full Text] [Related]
23. Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
Wirth K; Schoepf E; Mertelsmann R; Lindemann A
Br J Dermatol; 1998 Mar; 138(3):533-5. PubMed ID: 9580816
[TBL] [Abstract][Full Text] [Related]
24. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
[TBL] [Abstract][Full Text] [Related]
25. Anagrelide, a selective thrombocytopenic agent.
Oertel MD
Am J Health Syst Pharm; 1998 Oct; 55(19):1979-86. PubMed ID: 9784784
[TBL] [Abstract][Full Text] [Related]
26. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
[TBL] [Abstract][Full Text] [Related]
27. Treatment of children with anagrelide for thrombocythemia.
Lackner H; Urban C; Beham-Schmid C; Benesch M; Kerbl R; Schwinger W
J Pediatr Hematol Oncol; 1998; 20(5):469-73. PubMed ID: 9787322
[TBL] [Abstract][Full Text] [Related]
28. Reversible dilated cardiomyopathy associated with long-term anagrelide therapy in a patient with chronic myeloproliferative disease: a serial 2-dimensional speckle tracking echocardiographic study.
Lee SH; Kim YS
Int J Cardiol; 2014 May; 173(3):e45-6. PubMed ID: 24698230
[No Abstract] [Full Text] [Related]
29. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.
Hong Y; Erusalimsky JD
Platelets; 2002 Nov; 13(7):381-6. PubMed ID: 12487784
[No Abstract] [Full Text] [Related]
30. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany.
Petrides PE; Beykirch MK; Trapp OM
Eur J Haematol; 1998 Aug; 61(2):71-6. PubMed ID: 9714517
[TBL] [Abstract][Full Text] [Related]
31. Anagrelide for essential thrombocythemia.
Med Lett Drugs Ther; 1997 Dec; 39(1016):120. PubMed ID: 9422046
[No Abstract] [Full Text] [Related]
32. TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.
Palmblad J; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Mauritzson N; Westin J; Samuelsson J; Birgegård G
Int J Med Sci; 2008 Apr; 5(2):87-91. PubMed ID: 18414650
[TBL] [Abstract][Full Text] [Related]
33. Essential thrombocytemia progressing to Ph+ chronic myeloid leukemia with megakaryoblastic blasts, following anagrelide withdrawal.
Piccin A; Corvetta D; Rovigatti U; Mazzoleni G; Pusceddu I; Svaldi M; Steurer M; Gastl G; Cortelazzo S
Platelets; 2014; 25(8):646-7. PubMed ID: 24205832
[No Abstract] [Full Text] [Related]
34. Primary thrombocythemia: a current perspective.
Mughal TI
Stem Cells; 1995 Jul; 13(4):355-9. PubMed ID: 7549894
[TBL] [Abstract][Full Text] [Related]
35. A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.
Gisslinger H; Buxhofer-Ausch V; Hodisch J; Radinoff A; Karyagina E; Kyrcz-Krzemień S; Abdulkadyrov K; Gerbutavicius R; Melikyan A; Burgstaller S; Hus M; Kłoczko J; Yablokova V; Tzvetkov N; Całbecka M; Shneyder T; Warzocha K; Jurgutis M; Kaplanov K; Jilma B; Schoergenhofer C; Klade C
Br J Haematol; 2019 May; 185(4):691-700. PubMed ID: 30919941
[TBL] [Abstract][Full Text] [Related]
36. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results.
Mazzucconi MG; De Sanctis V; Chistolini A; Dragoni F; Mandelli F
Haematologica; 1992; 77(4):315-7. PubMed ID: 1427441
[TBL] [Abstract][Full Text] [Related]
37. [Anagrelide--new antiplatelet drug].
Robak T; Treliński J; Hołub A
Acta Haematol Pol; 1994; 25(4):309-15. PubMed ID: 7847031
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers.
Abe Andes W; Noveck RJ; Fleming JS
Thromb Haemost; 1984 Dec; 52(3):325-8. PubMed ID: 6531755
[TBL] [Abstract][Full Text] [Related]
39. Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.
Okamoto S; Miyakawa Y; Smith J; Hodgson I; Abhyankar B; Troy S; Kanakura Y
Int J Hematol; 2013 Mar; 97(3):360-8. PubMed ID: 23378182
[TBL] [Abstract][Full Text] [Related]
40. A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With Essential Thrombocythemia.
Singh P
J Pharm Pract; 2018 Apr; 31(2):230-233. PubMed ID: 28343445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
